ArticleCancers2022
Hyperpolarized
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-Abdominal radiology (New York) · 2026Trial
- A Static Phantom for Harmonization of Hyperpolarized [1-Magnetic resonance in medicine · 2026Article
- Hyperpolarized MRI in Oncology-A Review of Clinical Studies and Evaluation of Preclinical Liver Studies.NMR in biomedicine · 2026Review
- Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours UsingNMR in biomedicine · 2026Article
- Quantitative Imaging of Pyruvate Metabolism in a Patient With Anaplastic Thyroid Cancer.Magnetic resonance in medicine · 2026Article
- Technologies and Strategies for Metabolic and Molecular Imaging With Hyperpolarized MRI.Journal of magnetic resonance imaging : JMRI · 2026Review
- Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarisedCommunications medicine · 2026Article
- Radial multi-echo bSSFP and IDEAL chemical shift separation in k-space for high-speed 3D hyperpolarizedMagnetic resonance in medicine · 2025Article
- Open-source implementation of X-nuclear sequences using the Pulseq framework.Magnetic resonance in medicine · 2025Article
- A data-driven approach for improved quantification of in vivo metabolic conversion rates of hyperpolarized [1-Magnetic resonance in medicine · 2025Article
- In silico development and validation of a novel six-gene-derived signature in hepatocellular carcinoma.Translational cancer research · 2025Article
- Potential of Metabolic MRI to Address Unmet Clinical Needs in Localised Kidney Cancer.Cancers · 2025Review
- Temperature dependent chemical shifts of pyruvate and lactate enable in vivo hyperpolarizedNpj imaging · 2025Article
- Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-EJNMMI research · 2025Article
- Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.Oncogene · 2025Article
- K-Means Clustering of HyperpolarisedCancers · 2025Article
- Spatially constrained hyperpolarized 13C MRI pharmacokinetic rate constant map estimation using a digital brain phantom and a U-Net.Journal of magnetic resonance (San Diego, Calif. : 1997) · 2025Article
- Quo Vadis HyperpolarizedZeitschrift fur medizinische Physik · 2025Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 2 institutions in 1 country.
Stephan UrsprungCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-2476-178X
Ramona WoitekCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Mary A McLeanCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Andrew N PriestDepartment of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0002-9771-4290
Mireia Crispin-OrtuzarCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Cara R BrodieCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Andrew B GillCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0002-9287-9563
Marcel GehrungCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Lucian BeerCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-4388-7580
Antony C P RiddickDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Johanna Field-RaynerCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
James T GristDepartment of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK.
Surrin S DeenCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0002-6206-7337
Frank RiemerCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0002-3805-5221
Joshua D KaggieCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0001-6706-3442
Fulvio ZaccagnaCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0001-6838-9532
Joao A G DuarteCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Matthew J LockeCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Amy FraryCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Tevita F AhoDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
James N ArmitageDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Ruth CaseyDepartment of Endocrinology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Iosif A MendichovszkyCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Sarah J WelshCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0001-5690-2677
Tristan BarrettCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Martin J GravesDepartment of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Tim EisenCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0001-9663-4873
Thomas J MitchellCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Anne Y WarrenCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Kevin M BrindleCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-3883-6287
Evis SalaCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.
Grant D StewartCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-3188-9140
Ferdia A GallagherCancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0QQ, UK.ORCID 0000-0003-4784-5230
University of Cambridge · GBCambridge University Hospitals NHS Foundation Trust · GB
Funding
Austrian Science Fund FWF J 4025Cancer Research UK 16465Cancer Research UK 16628Cancer Research UK 27150Cancer Research UK 27176Cancer Research UK C19212/A16628Cancer Research UK C19212/A27150Cancer Research UK C19212/A911376Cancer Research UK C9685/A25117Medical Research Council MR/T024097/1Wellcome Trust 095962
Abstract
Differentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI following injection of hyperpolarized [1-
Indexed as
cancer metabolismhyperpolarized 13C magnetic resonance imagingmonocarboxylate transporterrenal cell carcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.